Macrolides Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Macrolides DMPK and Bioanalytical Services

Macrolide bioanalysis is rarely a simple parent-drug concentration task. This class brings together several study-defining analytical risks: CYP3A-mediated metabolism, P-gp or transporter-related interaction questions, active or structurally important metabolites, extensive tissue and intracellular distribution, plasma-to-tissue exposure disconnects, long terminal sampling windows, and multi-analyte interference in complex biological matrices.

For macrolide DMPK studies, the core analytical problem is not just whether erythromycin, clarithromycin, azithromycin, or roxithromycin can be detected by LC-MS/MS. The real challenge is whether the workflow explains what the measured concentration represents: parent-drug exposure, CYP3A4-mediated metabolism, active metabolite formation, tissue distribution, intracellular accumulation, biliary or non-renal elimination, or compatibility with a multi-macrolide panel.

Browse Macrolide Drug Index Request Custom Macrolide Method Support

CYP3A4-aware designConnect parent-drug quantification with metabolism and DDI-support endpoints when relevant.

Plasma-to-tissue disconnectHandle tissue, cell, and intracellular exposure questions beyond plasma-only analysis.

Metabolite-level clarityTrack active or structurally important metabolites such as 14-hydroxyclarithromycin.

Macrolide Workflow Risks DMPK Strategy Map

CYP

CYP3A-mediated metabolismErythromycin and clarithromycin workflows may be driven by enzyme interaction and metabolite endpoints.

🧬

Active metabolite trackingParent-only assays can miss 14-hydroxyclarithromycin or other transformation targets.

📍

Tissue and cell exposureMacrolides can require tissue homogenate, cell lysate, or intracellular sample strategies.

Panel selectivity pressureRelated macrolides differ in retention, ionization, metabolite targets, and dynamic range.

Interaction-aware workflow design.Creative Proteomics connects parent-drug quantification, CYP3A4 / P-gp-aware DDI support, active metabolite tracking, tissue distribution, plasma/serum bioanalysis, and custom macrolide panel development in one study-aware strategy.

Macrolide Drug Index

Find the Macrolide Compound Behind the Study

If you are dealing with a difficult biological matrix or tracking a specific metabolite, don't worry about standard classifications. Simply enter a compound name, filter A–Z, or combine field tags to zero in on the matching macrolide method and its analytical parameters.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only macrolides matching all selected values.

4 entries · Page 1 of 2

Analytical Pain Points

What Drives Assay Failure in Macrolide Studies?

Macrolide DMPK studies often fail when the assay is treated like a generic small-molecule quantification task. The compound may be easy to name, but the study can become difficult once CYP3A4 metabolism, active metabolites, transporter interaction, tissue accumulation, biliary or non-renal elimination, and matrix-dependent exposure are brought into the same workflow.

CYP3A4 Interaction Can Dominate the Study Question

For erythromycin and clarithromycin, CYP3A4 is not a background detail. It can define the entire DMPK problem. A parent-drug assay that ignores CYP3A4-mediated metabolism or inhibition risk may generate concentration data without answering the reason the study was outsourced.

Our responseCYP3A4-aware bioanalytical workflows where relevant, connecting parent-drug quantification, metabolite tracking, and DDI-support endpoints in the same study design.

DDI Support →

Parent Drug Alone May Miss the Active Metabolite Problem

Clarithromycin studies frequently require attention to 14-hydroxyclarithromycin. If parent and metabolite are not designed into the method early, the assay may be unable to support parent-metabolite exposure interpretation.

Our responseParent-metabolite LC-MS/MS workflows that separate parent macrolide signal from metabolite signal, support concentration range planning, and enable MetID when required.

MetID →

Plasma Concentration May Not Explain Tissue Exposure

Macrolides can show extensive distribution into tissues and intracellular compartments. Plasma concentration may be measurable, but it may not represent the exposure pattern of the tissue, cell, or intracellular model being studied.

Our responseMatrix-specific workflows for plasma, serum, tissue homogenates, cell lysates, and intracellular or phagocyte-enriched samples when distribution-aware interpretation is required.

Tissue & Cell Lysate Quantification →

Long Terminal Exposure Requires Late-Point Sensitivity

Azithromycin and related macrolide workflows can require late time-point measurement, low-level quantification, and careful interpretation of long exposure windows. A method that works only at early, high-concentration points may not support the full PK question.

Our responseSensitivity, LLOQ, selectivity, and calibration range planning around the expected sampling window, including late time points and tissue-enriched matrices.

LC-MS/MS Quantification →

Multi-Macrolide Panels Create Ionization and Selectivity Pressure

Erythromycin, clarithromycin, azithromycin, and roxithromycin are structurally related but analytically non-identical. A panel must account for different retention behavior, ionization efficiency, metabolite targets, dynamic ranges, and matrix behavior.

Our responseCustom LC-MS/MS panels that consider analyte compatibility, extraction strategy, chromatographic separation, MRM transitions, internal standard strategy, and matrix-matched calibration.

Custom Drug Panels →

Focused Service Paths

Four Practical Routes for Macrolide Studies

Instead of treating macrolides as one generic antibiotic class, the analytical route should be selected according to the study objective: parent-drug exposure, CYP3A4 / P-gp-related interaction support, metabolite tracking, tissue distribution, or custom panel development.

Parent Macrolide PK and Exposure Profiling

For studies that require parent-drug concentration data in plasma, serum, tissue, cell lysate, or another biological matrix.

Parent-drug quantification
Plasma or serum exposure profiling
Tissue or intracellular distribution studies
Time-course sample analysis

LC-MS/MS Drug Quantification →

CYP3A4-, P-gp-, and Transporter-Aware DDI Support

For studies where CYP3A4 metabolism, mechanism-based inhibition, P-gp interaction, or substrate / inhibitor behavior is part of the research question.

CYP3A4-related DDI support
Mechanism-based inhibition studies
Transporter-aware interpretation
Co-administered compound workflows

DDI Support →

MetID and Active Metabolite Tracking

For studies where parent-drug concentration alone is not enough and metabolite formation, active metabolite tracking, or structural confirmation is required.

14-hydroxyclarithromycin tracking
Erythromycin transformation products
Phase I metabolite profiling
HRMS-supported MetID

Metabolite Identification →

Macrolide Panel and Tissue Distribution Workflows

For studies involving multiple macrolides, anti-infective panels, tissue exposure, intracellular accumulation, or comparative matrix behavior.

Multi-macrolide quantification
Comparative anti-infective exposure
Tissue or cell lysate analysis
Custom analyte panel design

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Macrolide?

If you are working with a semi-synthetic macrolide, a novel macrolide scaffold, a metabolite, an active transformation product, a salt or formulation-related form, or a complex biological matrix, a standard parent-drug method may not be enough.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows for challenging macrolide and anti-infective analytes. Share your target compound, matrix, expected concentration range, CYP3A4 / P-gp or transporter concerns, metabolite targets, tissue distribution needs, and required readouts to initiate a feasibility review.

Target macrolide and analyte behavior

Matrix and expected concentration range

CYP3A4 / P-gp or transporter questions

Metabolite targets or active products

Tissue or intracellular distribution needs

Single-analyte assay or panel workflow